Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily …
2 天之前 · “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to ...
Vertex Announces US FDA Approval of ALYFTREK - Business Wire
1 天前 · Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily …
1 天前 · - In head-to-head clinical trials, ALYFTREK was non-inferior on ppFEV 1 and further decreased sweat chloride compared to TRIKAFTA ® - BOSTON, December 20, 2024--(BUSINESS WIRE)--Vertex ...
2024-12-20 | Vertex Announces US FDA Approval of ALYFTREK
1 天前 · “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex.
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily …
1 天前 · - ALYFTREK ™ is approved for patients 6 years and older with at least one responsive mutation, including 31 additional mutations not responsive to other CFTR modulator therapies - - In head-to ...
Vertex announces FDA approval of Alyftrek | Markets Insider
2 天之前 · Vertex Pharmaceuticals (VRTX) announced that the U.S. Food and Drug Administration has approved Alyftrek, a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance ...
Vertex's Cystic Fibrosis Drug Alyftrek Gets FDA Approval
1 天前 · (RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) Friday announced that the U.S. Food and Drug Administration (FDA) has approved Alyftrek for treatment of cystic fibrosis. Alyftrek is a once-daily ...
FDA Approves Alyftrek, Once-Daily CFTR Modulator for Cystic …
21 小时之前 · SKYLINE 102. Trial Name: A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/ MF) ClinicalTrials.gov ID: NCT05033080 Sponsor: Vertex Pharmaceuticals Incorporated Completion Date: November 21, 2023 SKYLINE 103. Trial Name: A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF ...
Vertex's Cystic Fibrosis Drug Alyftrek Gets FDA Approval
1 天前 · Vertex Pharmaceuticals Inc. (VRTX) Friday announced that the U.S. Food and Drug Administration (FDA) has approved Alyftrek for treatment of cystic fibrosis. Alyftrek is a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or ...
Vertex Announces US FDA Approval of ALYFTREK™, a Once
2 天之前 · Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis - ALYFTREK™ is approved for patients 6 years and older with at ...
- 某些结果已被删除